| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10157-013-0855-Z |
| P698 | PubMed publication ID | 24013763 |
| P2093 | author name string | David Jayne | |
| P2860 | cites work | Etanercept plus standard therapy for Wegener's granulomatosis | Q33984596 |
| Update on the European Vasculitis Study Group trials | Q34124975 | ||
| Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis | Q34708735 | ||
| A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. | Q34989833 | ||
| Rituximab versus cyclophosphamide for ANCA-associated vasculitis | Q35109118 | ||
| A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis | Q35878676 | ||
| Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index | Q37170449 | ||
| L41. Perspectives on the treatment of giant cell arteritis | Q38088030 | ||
| Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis | Q42122199 | ||
| A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies | Q42163521 | ||
| Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | Q42963758 | ||
| Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement | Q43109217 | ||
| Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations | Q43420991 | ||
| Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. | Q46117432 | ||
| Deoxyspergualin in relapsing and refractory Wegener's granulomatosis | Q46421721 | ||
| Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). | Q46869194 | ||
| Spleen tyrosine kinase is important in the production of proinflammatory cytokines and cell proliferation in human mesangial cells following stimulation with IgA1 isolated from IgA nephropathy patients. | Q54485643 | ||
| Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients | Q80244017 | ||
| Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome | Q84332714 | ||
| Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome | Q84893066 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 694-696 | |
| P577 | publication date | 2013-09-07 | |
| P1433 | published in | Clinical and experimental nephrology | Q26842022 |
| P1476 | title | New-generation therapy for ANCA-associated vasculitis | |
| P478 | volume | 17 |
Search more.